Curosurf (Poractant Alfa) - Summary

CUROSURF SUMMARY

CUROSURF® (poractant alfa) Intratracheal Suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only.

CUROSURF is indicated for the treatment (rescue) of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.

See all Curosurf indications & dosage >>

CUROSURF NEWS HIGHLIGHTS

Media Articles Related to Curosurf (Poractant Alfa)

ARDS (Acute Respiratory Distress Syndrome)
Source: MedicineNet Legionnaire Disease and Pontiac Fever Specialty [2007.03.12]

more >>

Published Studies Related to Curosurf (Poractant Alfa)

A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. [2005.06]

A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. [2005.04]

A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. [2004.04]

Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial. [2000.04.22]

Theoretical changes in neonatal hospitalisation costs after the introduction of porcine-derived lung surfactant ('Curosurf'). [1995.10]

more >>

Clinical Trials Related to Curosurf (Poractant Alfa)

Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants [Recruiting]

Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study [Recruiting]

Surfactant Application During Spontaneous Breathing With Continuous Positive Airway Pressure (CPAP) in Premature Infants < 27 Weeks [Not yet recruiting]

Synchronized Intermittent Mandatory Ventilation (SIMV) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) In Preterm Infants With Respiratory Distress [Recruiting]

Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis [Completed]

more >>